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INEFFECTIVE ERYTHROPOIESIS IN RECIPIENT PRECURSOR CELLS FOL-
LOWING NON-MYELOABLATIVE STEM CELL TRANSPLANTATION IN
PATIENTS WITH SEVERE SICKLE CELL ANEMIA
Wu, C.J.1,2, Rogers, S.A.1, Kutok, J.3, Krishnamurti, L.4, Hochberg,
E.P.1,2, Biernacki, M.1, Antin, J.H.1,2, Ritz, J.1,2 1. Department of
Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 2. De-
partment of Medicine, Brigham and Women’s Hospital, Boston, MA; 3.
Department of Pathology, Brigham and Women’s Hospital, Boston, MA;
4. Pediatric Hematology/Oncology/BMT, Children’s Hospital of Pitts-
burgh, Pittsburgh, PA.
After nonmyeloablative (NMA) stem cell transplantation (SCT),
we observed greater clinical improvement in sickle cell disease
(SCD)-associated symptoms than anticipated by the degree of
chimerism established by routine genotyping of marrow or periph-
eral blood cells in some patients. We hypothesized that RBC
chimerism would provide a more accurate assessment of functional
donor hematopoiesis. -globin RNA pyrosequencing can be used
to quantify erythroid-speciﬁc lineage chimerism following trans-
plant. In this method, direct quantitative sequencing of the sickle
mutation in -globin RNA serves as an informative locus to dis-
tinguish between recipient and donor erythropoiesis. This analysis
was performed on serial samples collected from 3 patients with
severe SCD with HLA-matched related donors who underwent
NMA-SCT. -globin RNA chimerism in peripheral blood (PB)
and marrow (BM) was compared to total genomic DNA chimerism
and DNA chimerism of phenotypically deﬁned erythroid lineage
precursor cells. All patients demonstrated stable mixed donor
DNA chimerism in the ﬁrst 60-100 days, at levels of 25-30%,
40-50% and 56-60% in Pts 1, 2 and 3, respectively, with no
difference between PB and BM levels. DNA chimerism of BM
erythroid precursors, determined by Y chromosome FISH and
ABO staining in Pts 1 and 2, were identical to total BM gDNA
chimerism. In contrast, all 3 patients demonstrated a 2 fold
greater level of -globin RNA chimerism in PB and marrow
compared with gDNA chimerism, with 45/55%, 100/100% and
100/100% BM/PB% donor -globin RNA measured in Pts 1, 2
and 3, respectively. The consistently increased levels of donor
derived -globin RNA detected in marrow samples, compared to
the lower levels of erythroid DNA chimerism suggest that recipi-
ent erythroid precursor cells with sickle hemoglobin do not effec-
tively mature into peripheral RBC. In patients with mixed hema-
topoietic chimerism after NMA-SCT, donor erythroid precursor
cells have a maturation advantage that allows for greater donor
contribution to overall erythropoiesis. This advantage is likely
further accentuated by the shortened survival of recipient RBC.
Further studies are underway to characterize the mechanisms that
lead to ineffective SCD erythropoiesis in these patients.
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BEAM ALLOGENEIC TRANSPLANT IN PATIENTS FAILING AUTOLOGOUS
TRANSPLANTATION FOR HODGKIN’S DISEASE OFFERS AN OPPORTU-
NITY FOR LONG-TERM SURVIVAL
Stilwill, J.F., Toor, A.A., Rodriguez, T.E., Strupeck, J., Parthasarathy,
M., Stiff, P.J. Loyola University Medical Center, Maywood, IL.
While the current standard of care for refractory Hodgkin’s
disease is an autologous stem cell transplant, patients who fail this
form of therapy usually receive only palliative therapy. With the
possibility of reduced-intensity allografts decreasing toxicity seen
previously with ablative transplants and a presumed graft-versus-
lymphoma effect, we began a program in 2000 to perform alloge-
neic transplants with BEAM conditioning in patients with
Hodgkin’s disease who had failed autologous transplant. We have
treated 13 patients to date using graft-versus-host-disease
(GVHD) prophylaxis with mini-methotrexate and FK-506 with
early weaning from day 60 to day 80. The median age at allograft
was 35 (range: 21 to 48). Median time from diagnosis to allograft
was 69 months (range: 12 to 172 months), from autograft to relapse
was 11 months (range: 0 to 44 months) and from relapse following
autograft to allograft was 31 months (range: 2 to 105 months).
Median number of relapses from diagnosis was 4 (range: 2 to 6). Of
the 13 patients, 11 had chemoresistant disease, 8 had bulky disease
(bulk 2 cm in diameter), 3 had extranodal disease and 5 had
relapsed disease in a prior radiation port at allograft. Patients
received either matched sibling peripheral blood stem cells (5),
partially matched sibling bone marrow (1), or matched unrelated
bone marrow (7). At a median of 29 months from allograft (range:
2 to 41 months), 6 of 13 patients (46%) are alive and all are
currently in complete remission (CR). Of the 7 patients that died,
1 died of sepsis during hospitalization, 2 expired without evidence
of disease (GVHD; CHF), and 4 expired due to progressive dis-
ease. Nine patients developed chronic GVHD including 5 of 6 in
CR (1 too early). Two patients received donor lymphocyte infu-
sions (DLI) following relapse resulting in transient improvement in
one and a CR in the other. Given that 46% are alive with no
evidence of disease, this compares favorably with accepted indica-
tions for allogeneic transplant after failed autograft for Non-
Hodgkin’s lymphoma. Allogeneic transplant offers a signiﬁcant
opportunity for long-term survival in patients with Hodgkin’s
disease that have failed autologous transplant, even those with
chemoresistant disease and without matched related donors, and
should be considered an important option in all such patients.
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SINGLE INSTITUTION EXPERIENCE WITH HHV6 INFECTIONS IN THE
PEDIATRIC HSCT PATIENTS
Olson, E.A.1, Chiang, K.Y.1, Haight, A.E.2, Bowman, L.2 1. Children’s
Healthcare of Atlanta, Atlanta, GA; 2. Emory University, Atlanta, GA.
Reactivated Herpes family viral infections continue to cause
morbidity and mortality during hematopoietic stem cell transplant
(HSCT). Routine monitoring and prophylactic or preemptive
therapy for CMV during the peritransplant period are now ac-
cepted standards of care in allogeneic HSCT. Other viral infec-
tions such as Human Herpesvirus 6 (HHV6) have been increas-
ingly identiﬁed as a signiﬁcant cause of morbidity during HSCT.
New technology with quantitative PCR testing permits more rapid
diagnosis of HHV6 reactivation. During an eight-month period at
our institution ﬁve out of nine allogeneic HSCT patients (55%)
were diagnosed with HHV6 infection, no autologous patients
tested positive. All received acyclovir prophylaxis. Graft source and
indication for HSCT were: one matched sibling with MDS; one
unrelated cord blood for infant leukemia; and three T-cell depleted
matched unrelated transplants for CML. Three of the patients
presented with respiratory distress with diffuse alveolar hemor-
rhage. Bronchial alveolar lavage (BAL) was positive for HHV6 by
PCR on all three patients. The other two had central nervous
system (CNS) manifestation; one had a seizure and the other had
progressive mental status changes. Spinal ﬂuids from both patients
were positive for HHV6 by PCR. Four of the patients were treated
with Ganciclovir; the ﬁfth patient received Foscarnet since this
patient was already on Ganciclovir for CMV infection. Two of the
patients responded initially to the Ganciclovir with a decrease in
HHV6 quantitative PCR level, but the PCR increased and symp-
toms worsened requiring a switch to Foscarnet. The other three
continued to have progressive deterioration from the HHV6.
HHV6 was the cause of death in all ﬁve patients. These case
reports demonstrate the emergence of HHV6 as a signiﬁcant viral
pathogen in allogeneic HSCT patients. Vigilant clinical observa-
tion with routine monitoring of HHV6 by a sensitive and reliable
test and prompt treatment with appropriate antiviral agents may
allow improved outcome for this deadly viral infection.
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T CELL (CD3) CHIMERISM AFTER NON-MYELOABLATIVE ALLOGE-
NEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (NMHSCT)
Sobecks, R., Theil, K., Rybicki, L., Kuczkowski, E., Warshawsky, I.,
Tubbs, R., Kalaycio, M., Pohlman, B., Andresen, S., Bolwell, B.J. The
Cleveland Clinic Foundation, Cleveland, OH.
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